Pharmacokinetics of bempedoic acid in patients with renal impairment

por Amore, Benny M., Sasiela, William J., Ries, Daniel K., Tresh, Perry, Emery, Maurice G.
Publicado 2021

Absence of effect of steady state bempedoic acid on cardiac repolarization: Results of a thorough QT/QTc study in healthy volunteers

por Amore, Benny M., Cramer, Clay T., MacDougall, Diane E., Sasiela, William J., Emery, Maurice G.
Publicado 2021

Population pharmacokinetics and exposure–response modeling and simulation for evolocumab in healthy volunteers and patients with hypercholesterolemia

por Kuchimanchi, Mita, Grover, Anita, Emery, Maurice G., Somaratne, Ransi, Wasserman, Scott M., Gibbs, John P., Doshi, Sameer
Publicado 2018

Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor

por Kasichayanula, Sreeneeranj, Grover, Anita, Emery, Maurice G., Gibbs, Megan A., Somaratne, Ransi, Wasserman, Scott M., Gibbs, John P.
Publicado 2018

Physiologically Based Pharmacokinetic Model Development and Verification for Bioequivalence Testing of Bempedoic Acid Oral Suspension and Reference Tablet Formulation

por Amore, Benny M., Patel, Nikunjkumar, Batheja, Priya, Templeton, Ian E., Jones, Hannah M., Louie, Michael J., Emery, Maurice G.
Publicado 2023

Population pharmacokinetic and pharmacokinetic-pharmacodynamic modeling of bempedoic acid and low-density lipoprotein cholesterol in healthy subjects and patients with dyslipidemia

por Jadhav, Satyawan B., Amore, Benny M., Bockbrader, Howard, Crass, Ryan L., Chapel, Sunny, Sasiela, William J., Emery, Maurice G.
Publicado 2023

Influence of Renal Function on Evolocumab Exposure, Pharmacodynamics, and Safety

por Lee, Edward, Gibbs, John P., Emery, Maurice G., Block, Geoffrey, Wasserman, Scott M., Hamilton, Lisa, Kasichayanula, Sreeneeranj, Hanafin, Patrick, Somaratne, Ransi, Egbuna, Ogo
Publicado 2019

Evaluation of Evolocumab (AMG 145), a Fully Human Anti‐PCSK9 IgG2 Monoclonal Antibody, in Subjects With Hepatic Impairment

por Gibbs, John P., Slatter, J. Greg, Egbuna, Ogo, Geller, Michelle, Hamilton, Lisa, Dias, Clapton S., Xu, Ren Y., Johnson, Jessica, Wasserman, Scott M., Emery, Maurice G.
Publicado 2016

Impact of Target‐Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)

por Gibbs, John P., Doshi, Sameer, Kuchimanchi, Mita, Grover, Anita, Emery, Maurice G., Dodds, Michael G., Gibbs, Megan A., Somaratne, Ransi, Wasserman, Scott M., Blom, Dirk
Publicado 2016

Pharmacodynamic effect of bempedoic acid and statin combinations: predictions from a dose–response model

por Jadhav, Satyawan B, Crass, Ryan L, Chapel, Sunny, Kerschnitzki, Michael, Sasiela, William J, Emery, Maurice G, Amore, Benny M, Barrett, P Hugh R, Watts, Gerald F, Catapano, Alberico L
Publicado 2021